Calysta Energy™ (www.calystaenergy.com) today announced Craig H. Barratt, Ph.D., has been elected to the company’s Board of Directors. Dr. Barratt, a leading consumer electronics entrepreneur, is the former president of Qualcomm Atheros, the network and connectivity subsidiary of Qualcomm. Calysta is using natural gas as a new biological feedstock for cost competitive, scalable chemicals and biofuels production.

“We are honored to have Craig Barratt join the Calysta Board,” said Alan Shaw, Ph.D., Chairman, President and CEO. “He is a visionary entrepreneur who knows how to recognize disruptive technology and build valuable companies. As our company enters an important new stage of growth, he will be a valued addition to Calysta.”

Dr. Barratt joined Qualcomm in 2011. From 2003, he was president, CEO and a director of Atheros Communications, a fabless semiconductor company. He led the company through its 2004 IPO and growth to over $900 million in revenue in 2010, culminating in its 2011 acquisition by Qualcomm.

Dr. Barratt previously served as Atheros’ vice president of technology from 2002 until 2003. Prior to joining Atheros, he held the role of executive vice president and general manager of ArrayComm, a company specializing in multi-antenna signal processing.

Dr. Barratt holds Ph.D. and Master of Science degrees in electrical engineering from Stanford University, as well as a Bachelor of Engineering degree in electrical engineering and a Bachelor of Science degree from the University of Sydney in Australia. Dr. Barratt has been granted over 30 patents in a variety of wireless and related technologies and has co-authored a book on linear controller design, various technical publications and open source software.

About Calysta Energy

Calysta Energy, LLC. (www.calystaenergy.com), Menlo Park, CA., is developing a new biological gas-to-liquids™ (BioGTL™) technology using methane – an energy-rich component of natural gas – as a new biological feedstock for high value industrial chemicals and transportation fuels with cost and performance advantages over current processes. The company is a spinout of DNA2.0, the largest US-based provider of synthetic genes for industrial and academic use.